Now showing items 1-2 of 2

    • CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. 

      Lim, JSJ; Turner, NC; Yap, TA (2016-07)
      Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ...
    • Treating cancer with selective CDK4/6 inhibitors. 

      O'Leary, B; Finn, RS; Turner, NC (2016-07)
      Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ...